SCHEMBL6300158

SCHEMBL6300158

COc1cccc(CO)c1CC(C)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
ATM Q13315 1/20 0.47
BCHE P06276 1/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
CYP2D6 P10635 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
HTR7 P34969 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KCNH2 Q12809 1/20 0.39
TRPA1 O75762 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
OPRK1 P41145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6301961 0.85 ATM (0.47) L3MBTL1ATMBCHEKMT2AMEN1
SCHEMBL6301924 0.82 LMNA (0.43) L3MBTL1ATMKMT2AMEN1CRHBP
SCHEMBL4765000 0.79 PDE4A (0.47) L3MBTL1ATMKMT2AMEN1TRPA1
SCHEMBL6301275 0.78 HPGD (0.49) KMT2AMEN1CRHBPCRHR2ALDH1A1
SCHEMBL6300266 0.78 CYP4F2 (0.49) L3MBTL1ATMKMT2AMEN1CRHBP
SCHEMBL1029593 0.77 PDE4A (0.45) L3MBTL1ALDH1A1HPGDHSD17B10
SCHEMBL14042175 0.75 ATM (0.42) L3MBTL1ATMBCHEKMT2AMEN1
SCHEMBL6300999 0.75 HSP90AA1 (0.50) L3MBTL1KMT2AMEN1HPGD
SCHEMBL16954472 0.74 ALOX5 (0.45) L3MBTL1ALDH1A1HPGDHSD17B10
SCHEMBL6307957 0.73 KDM4E (0.59) ATMBCHEKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6943183-B2 5-substituted tetralones as inhibitors of ras farnesyl transferase PFIZER INC (US) 2005-09-13 US disclosed
US-20040044057-A1 5- substituted tetralones as inhibitors of ras farnesyl trransferase WARNER-LAMBERT COMPANY 2004-03-04 US disclosed
EP-1276725-A2 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 2003-01-22 EP disclosed
WO-2001079180-A2 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044057-A1 5- substituted tetralones as inhibitors of ras farnesyl trransferase PTAR1, FNTA, GGPS1 L3MBTL1 1805/4885ATM 4089/4885BCHE 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.